Lumos Diagnostics Holdings Ltd. (AU:LDX) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lumos Diagnostics has secured a $41.38/test reimbursement rate for its FebriDx diagnostic test from the Centers for Medicare and Medicaid Services, effective January 2025. The approval is expected to enhance accessibility and adoption of FebriDx, which helps differentiate between bacterial and viral infections, addressing antibiotic resistance concerns. This milestone is seen as a significant step in the U.S. commercialization strategy for Lumos’ innovative diagnostic solutions.
For further insights into AU:LDX stock, check out TipRanks’ Stock Analysis page.